Avenue Therapeutics Inc. (ATXI)
0.26
0.01 (1.96%)
At close: Apr 08, 2025, 12:24 PM
0.26
0.00%
After-hours: Apr 08, 2025, 12:24 PM EDT
1.96% (1D)
| Bid | 0.26 |
| Market Cap | 819.24K |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -16.15M |
| EPS (ttm) | -15.79 |
| PE Ratio (ttm) | -0.02 |
| Forward PE | -0.44 |
| Analyst | n/a |
| Ask | 0.31 |
| Volume | 1,200 |
| Avg. Volume (20D) | 491,796 |
| Open | 0.26 |
| Previous Close | 0.26 |
| Day's Range | 0.26 - 0.26 |
| 52-Week Range | 0.26 - 11.63 |
| Beta | -0.29 |
About ATXI
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York....
Industry Biotechnology
Sector Healthcare
IPO Date Jun 27, 2017
Employees 3
Stock Exchange NASDAQ
Ticker Symbol ATXI
Website https://www.avenuetx.com
11 months ago
-27.26%
Avenue Therapeutics shares are trading lower after...
Unlock content with
Pro Subscription
11 months ago
-29.65%
Avenue Therapeutics shares are trading lower after the company announced a reverse stock split.
